BridgeBio Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BridgeBio Pharma 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BBIO

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. 

CEO
Neil Kumar
CEONeil Kumar
Employees
839
Employees839
Headquarters
Palo Alto, California
HeadquartersPalo Alto, California
Founded
2015
Founded2015
Employees
839
Employees839

BBIO Key Statistics

Market cap
14.39B
Market cap14.39B
Price-Earnings ratio
-19.62
Price-Earnings ratio-19.62
Dividend yield
Dividend yield
Average volume
1.63M
Average volume1.63M
High today
$74.94
High today$74.94
Low today
$70.22
Low today$70.22
Open price
$70.22
Open price$70.22
Volume
2.34M
Volume2.34M
52 Week high
$84.94
52 Week high$84.94
52 Week low
$28.33
52 Week low$28.33

Stock Snapshot

As of today, BridgeBio Pharma(BBIO) shares are valued at $73.88. The company's market cap stands at 14.39B, with a P/E ratio of -19.62.

As of 2026-03-31, BridgeBio Pharma(BBIO) stock has fluctuated between $70.22 and $74.94. The current price stands at $73.88, placing the stock +5.2% above today's low and -1.4% off the high.

The BridgeBio Pharma(BBIO)'s current trading volume is 2.34M, compared to an average daily volume of 1.63M.

During the past year, BridgeBio Pharma(BBIO) stock moved between $28.33 at its lowest and $84.94 at its peak.

During the past year, BridgeBio Pharma(BBIO) stock moved between $28.33 at its lowest and $84.94 at its peak.

BBIO News

TipRanks 1d
BridgeBio Files NDA for LGMD2I/R9 Oral Therapy

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 5d
A Look At BridgeBio Pharma Valuation As New Acoramidis Phase 3 Data Draws Market Attention

BridgeBio Pharma (BBIO) is in focus after announcing it will share long term efficacy and safety data for acoramidis in ATTR-CM at the American College of Cardi...

A Look At BridgeBio Pharma Valuation As New Acoramidis Phase 3 Data Draws Market Attention

Analyst ratings

95%

of 22 ratings
Buy
95.5%
Hold
4.5%
Sell
0%

People also own

Based on the portfolios of people who own BBIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.